Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29603099 | 1.00 | GAA (0.50) | GAAMAPTPARP1 | |
| Trifluoroacetic Acid SCHEMBL2246823 | 0.82 | CES1 (0.36) | GAAMAPT | |
| SCHEMBL290837 | 0.74 | — | — | |
| SCHEMBL6857914 | 0.73 | GAA (0.33) | GAAMAPT | |
| SCHEMBL5314863 | 0.70 | ALDH1A1 (0.33) | GAAMAPT | |
| SCHEMBL14644353 | 0.69 | CYP1A2 (0.32) | GAAMAPT | |
| Iminostilbene SCHEMBL29926907 | 0.67 | MAPT (1.00) | GAAMAPT | |
| Iminostilbene SCHEMBL75288 | 0.67 | MAPT (1.00) | GAAMAPT | |
| SCHEMBL184659 | 0.67 | MAPT (0.52) | GAAMAPT | |
| SCHEMBL452873 | 0.65 | GAA (0.44) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 902 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861128-A | Polymerizable compound and optically anisotropic body | 江苏创拓新材料有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-105348282-B | A kind of HIV-1 integrase inhibitor compounds and its preparation method and application | 北京工业大学 | 2018-06-29 | — | — | CN | claimed |
| CN-107531682-A | Maleate salts of B-RAF kinase inhibitors, crystalline forms, processes for their preparation and their use | 百济神州有限公司 | 2018-01-02 | — | — | CN | claimed |
| EP-2602242-A1 | PROCESS FOR PREPARING COMPOUND BY NOVEL SANDMEYER-LIKE REACTION USING NITROXIDE RADICAL COMPOUND AS REACTION CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-12 | — | — | EP | claimed |
| US-20130144061-A1 | PROCESS FOR PREPARING A COMPOUND BY A NOVEL SANDMEYER-LIKE REACTION USING A NITROXIDE RADICAL COMPOUND AS A REACTION CATALYST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-06 | — | — | US | claimed |
| EP-1852420-B1 | Indole compounds for treating respiratory disorders | ONO PHARMACEUTICAL CO (JP) | 2012-10-17 | — | — | EP | claimed |
| US-8153625-B2 | Nitrogen-containing heterocyclic compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | claimed |
| EP-1910379-B1 | CASPASE INHIBITOR PRODRUGS | VERTEX PHARMA (US) | 2011-10-19 | — | — | EP | claimed |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-16 | — | — | US | claimed |
| US-7879891-B2 | such as (S)-Carbazole-9-carboxylic acid 1-(3a-fluoromethyl-5-oxo-3a,5,6,6a-tetrahydro-furo[3,2-d]oxazol-2-yl)-2-methyl-propyl ester, used for the treatment of diseases related to inflammatory or degenerative conditions | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | claimed |
| EP-1740614-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | Theraptosis S.A. (FR) | 2007-01-10 | — | — | EP | claimed |
| US-7074782-B2 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-07-11 | — | — | US | claimed |
| WO-2005105829-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | THERAPTOSIS S.A. (FR) | 2005-11-10 | — | — | WO | claimed |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-18 | — | — | US | claimed |
| EP-1392289-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030092703-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| EP-1268425-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2003-01-02 | — | — | EP | claimed |
| WO-2002094263-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-28 | — | — | WO | claimed |
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-03-07 | — | — | US | claimed |
| WO-2001072707-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-10-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | GAA 3111/4885MAPT 4419/4885PARP1 1630/4885 |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | GAA 4099/4885MAPT 4550/4885PARP1 1806/4885 |
| US-20130144061-A1 | PROCESS FOR PREPARING A COMPOUND BY A NOVEL SANDMEYER-LIKE REACTION USING A NITROXIDE RADICAL COMPOUND AS A REACTION CATALYST | TYR, NOX5, NOXO1 | GAA 2809/4885MAPT 3467/4885PARP1 4680/4885 |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | GAA 3111/4885MAPT 4419/4885PARP1 1630/4885 |
| US-20030092703-A1 | Caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | GAA 3199/4885MAPT 4629/4885PARP1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.